Boston, MA 09/25/2014 (wallstreetpr) – Inovio Pharmaceuticals Inc (NASDAQ:INO) and Seoul-based GeneOne Life Science Inc (KRX:011000) have announced plans to conduct human trial on Ebola vaccine by 2015.
Inovio and GeneOne have advanced to the next level with their Ebola treating DNA vaccine and are seeking to start human trails by the next year. The two companies have joined the league of peer pharmaceutical companies with the advancement in developing a preventive cure for the deadly virus, reports a Wall Street Journal article.
Success On Animals
As of now, the partners are engaged in a pre-investigational study for new a drug and will begin the first Phase of the clinical trial in 2015. Inovio, with the global DNA vaccine maker, seek a third party support to carry on their research. They are on a look-out for resources to further develop, as well as commercialize their product after the success of the first Phase.
Inovio Pharmaceuticals Inc (NASDAQ:INO) highlighted yesterday that during preclinical tests of the Ebola vaccine, it has been developing, it achieved 100% success results in mice and guinea pigs. All the animals were exposed to Ebola virus, but were successfully saved from death, the company explained. The company’s immunotherapy treatment and vaccine drug is based on the SynCon technology that fights against several disease-specific antigens. Inovio’s President and Chief Executive Officer, Dr. J. Joseph Kim announced that the company is making accelerated efforts to fight the threat of Ebola.
Other Ongoing Researches
Several pharmaceutical companies have been engaged in developing a successful vaccine against the deadly Ebola virus that is threatening Africa. Apart from Inovio Pharmaceuticals Inc (NASDAQ:INO) and GeneOne’s plans to carry-out a joint study, others like Johnson & Johnson (NYSE:JNJ) has also made some announcements in this regards recently. It is speeding-up the development of a vaccine, it reported. Apart from this, GlaxoSmithKline plc (ADR) (NYSE:GSK) is also seeking to initiate human trials on the experimental vaccine it has been developing. GlaxoSmith had previously achieved successful results from trials on monkeys.